Giovanni Scambia

Plain English
This paper examines the status of simulation-based education in Italian healthcare, focusing on how it can improve skills and patient safety over the last 20 years. Experts found that while many initiatives exist, there are no national standards, which limits its effectiveness. They recommend creating a national registry for simulation programs, setting accreditation criteria, and integrating simulation training into healthcare education to enhance patient care and safety. Who this helps: This helps patients and healthcare providers by improving the quality of care and safety in healthcare settings.

Plain English
This study looked at a new treatment for hard-to-heal gastrointestinal defects, using a special tissue created from fat taken from the patient’s own body. In a trial with 30 patients, 93% of those with esophageal defects completely healed after the treatment, while about 60% of those with rectal defects saw improvement. This matters because it offers a promising option for patients with tough GI problems who haven't benefited from standard treatments. Who this helps: Patients with challenging gastrointestinal defects.

Plain English
This study focused on creating and testing an Italian version of a questionnaire used to assess symptoms in patients with bladder pain syndrome, also known as interstitial cystitis (BPS/IC). Researchers worked with 102 patients and 51 healthy volunteers, and found that the new Italian questionnaire accurately reflects the symptoms experienced by patients and differentiates them from healthy individuals. This matters because it allows Italian-speaking doctors to effectively evaluate and understand the needs of BPS/IC patients using a validated tool. Who this helps: This benefits patients with bladder pain syndrome and the doctors treating them.

Plain English
This study looked at whether an extra ultrasound scan in the late third trimester (between 35 and 37 weeks) helps identify babies that are smaller than expected at birth, without increasing risks for cesarean sections or other complications. The researchers found that the additional scan increased the detection of small babies from 0% to about 19.5%, and reduced the number of newborns needing intensive care from 3.8% to 1%. This matters because it suggests that an extra scan can help doctors spot potential problems earlier, leading to better outcomes for newborns without increasing surgery rates. Who this helps: This benefits expecting mothers and their babies, particularly in low-risk pregnancies.

Plain English
This study examined a new treatment strategy for women with advanced ovarian cancer that doesn't have a specific genetic mutation (non-BRCA). Researchers compared three treatment groups: one group received the standard care, while two others added a drug called durvalumab and one of those added olaparib to the mix. They found that the group receiving durvalumab and olaparib had a longer time without disease progression, lasting on average 37.3 months compared to 23 months for standard care. Who this helps: This research benefits patients with newly diagnosed advanced ovarian cancer who do not have BRCA mutations.

Plain English
This study looked at the complications and chances of recurrence after a major surgery called pelvic exenteration for certain types of gynecologic cancers. Researchers analyzed data from 862 patients and found that while only 0.8% had severe issues during the surgery itself, about 26.1% experienced serious complications shortly afterward, and 3.1% died within 30 days. This matters because it helps doctors understand risks associated with this surgery and provides a new scoring system to better inform and prepare patients for potential outcomes. Who this helps: Patients facing pelvic exenteration surgery and their healthcare providers.

Plain English
This study focused on how ovarian cancer spreads to the brain, which is becoming more common and is linked to poor outcomes. Researchers examined tissue samples from both the original tumors and the brain metastases and found that they were genetically similar, identifying specific pathways involved in this spread. They discovered potential biomarkers, like AFP and GFAP, that could help track brain metastases and suggest new treatment targets. Who this helps: This research benefits ovarian cancer patients by providing information that could lead to better treatments and care.

Plain English
This study looked at how well a new method called ctDNA-RECIST (cRECIST) can evaluate treatment responses in patients with HER2-positive metastatic breast cancer who were given a specific drug called Trastuzumab-emtansine (T-DM1). Researchers found that cRECIST identified treatment responses more accurately than traditional methods: in a group of 50 patients, cRECIST responses were deeper than standard response evaluations, indicating better outcomes in 27 patients. This is important because using cRECIST can lead to more personalized treatment strategies and help ensure patients do not stop effective treatments too soon. Who this helps: This benefits patients undergoing treatment for HER2-positive metastatic breast cancer.

Plain English
This study looked at how the molecular characteristics of endometrial cancer (EC) change from the time of diagnosis to when the cancer comes back. Researchers reviewed the cases of 221 patients who had surgery for EC between 2016 and 2020 and found that 18 of them experienced a recurrence. While only 2 cases showed a change in molecular classification, this highlights the need for more research to better understand these changes and their implications for treatment. Who this helps: This helps doctors and patients by providing insights for better cancer management and treatment strategies.

Plain English
The ERGO study surveyed over 1,000 surgeons from 42 countries to understand ergonomic problems they face in the operating room. The results showed that 96.9% of surgeons experienced some form of musculoskeletal discomfort, with issues being most common in laparoscopic surgery (55.4%). Despite these challenges, about 73% of surgeons reported never receiving any formal training on ergonomics, highlighting a significant gap in preparing them to prevent injuries that can affect their ability to work. Who this helps: This research helps surgeons who are at risk of physical injuries and the patients they care for.

Plain English
This study looked at how well two different testing methods agree in identifying a specific problem in cancers of the colon and uterus: mismatch repair deficiency (a genetic issue that can affect treatment outcomes). In a group of 520 patients, the tests matched almost perfectly for colon cancer (99% agreement), but only 85% of the time for endometrial cancer. This matters because it shows that the tests may not work as well for uterine cancer, where some genetic problems could lead to missed diagnoses. Who this helps: This research is important for doctors and patients with endometrial cancer who rely on accurate diagnostics for effective treatment.

Plain English
This study focused on creating a machine-learning model using ultrasound images to differentiate between uterine sarcomas, a type of cancer, and leiomyomas, which are usually benign growths. The researchers analyzed data from 200 patients and found that their best model had an accuracy rate of 93% in identifying uterine sarcomas, which means it correctly distinguished them from leiomyomas most of the time. This is important because it can lead to quicker and more accurate diagnoses, helping doctors to provide better care for patients. Who this helps: Patients with suspected uterine tumors who need accurate diagnoses.

Plain English
This study looked at high-grade serous ovarian cancer (HGSOC), which is an aggressive form of cancer that often does not respond well to treatment. Researchers analyzed patient-derived organoids (miniature versions of tumors) and discovered that these tumors have a mix of different cell types, with some being active and others not. Specifically, they found that the presence of cells relying on certain metabolic processes made the cancer more resistant to chemotherapy, meaning that targeting these cells could lead to better treatment strategies. Who this helps: This research benefits patients with high-grade serous ovarian cancer as it may lead to more effective treatment options.

Plain English
This study looked at whether features from PET scans taken before and after treatment could help predict outcomes for patients with locally advanced cervical cancer. Researchers analyzed data from 95 patients and found that 31.6% had cancer progression and 20% died from the disease after an average follow-up of over six years. The models created from PET scan features could slightly improve predictions for patient survival, but they weren’t reliable enough to make a real difference in clinical practice. Who this helps: This research helps doctors understand the limitations of using PET scan features for predicting outcomes in cervical cancer patients.

Plain English
This study looked at the role of isolated tumor cells (ITC) in endometrial cancer and how they relate to cancer spread and characteristics. Among nearly 1,900 patients, ITC were found in 5.1% of cases, and these patients showed more severe disease features, such as deep tissue invasion (67.7% compared to 28.7% in patients without cancer spread). The findings indicate that ITC might be an early sign of cancer spread and have a different, potentially less aggressive nature compared to larger metastases, which can improve how doctors assess risk and manage treatment for affected patients. Who this helps: Patients with endometrial cancer.

Plain English
This research study tested a drug called rucaparib as a continued treatment for women with recurring ovarian cancer that responds to platinum-based chemotherapy. The results showed that patients taking rucaparib had a longer time without their disease worsening—26.1 months compared to 18.4 months for those on a placebo. The study found that rucaparib did not significantly improve overall survival compared to the placebo but is still recommended for maintaining treatment benefits. Who this helps: This helps patients with recurrent, platinum-sensitive ovarian cancer.

Plain English
This study looked at how the amount of cancer present in the body before surgery affects survival outcomes for patients with advanced ovarian cancer. Researchers found that patients with a lower "tumor load" score (0-6) had a median survival time of 27 months without their cancer getting worse, compared to just 16 months for those with a higher score (8-12). This is important because it shows that knowing how much cancer is present can help doctors predict how well patients will do after treatment. Who this helps: Patients with advanced ovarian cancer and their doctors.

Plain English
This study looked into a rare skin cancer called vulvar Paget's disease (VPD), which affects 1-2% of vulvar cancers. Researchers found that the HER2 protein, which can be targeted by specific drugs, is present in 30-40% of VPD cases, and 121 out of 270 patients (about 45%) had high levels of HER2. They discovered that treatments targeting HER2, like trastuzumab, could potentially improve outcomes for patients, but more rigorous clinical trials are needed to confirm these findings. Who this helps: This benefits patients with vulvar Paget's disease by exploring new treatment options.

Plain English
The AZIMUTH study is testing a smartphone app designed to improve care for patients with heart failure, a condition that often leads to hospitalizations. Researchers will track 300 heart failure patients over six months to see how well the app helps them manage their health compared to traditional care. The goal is to reduce hospital visits and improve patient outcomes, showing how digital tools can enhance heart failure management. Who this helps: This benefits heart failure patients and their healthcare providers.

Plain English
This study looked at a rare type of uterine cancer called endometrial carcinosarcoma that hasn't spread to the muscle layer of the uterus. Researchers followed 97 patients who had surgery for this cancer and found that after five years, 63.5% were free from recurrence, while 72% were still alive. Many patients experienced cancer returning, often in distant areas of the body, highlighting the serious nature of this condition. Who this helps: This information is important for doctors treating patients with this rare cancer as it guides treatment decisions and patient counseling.

Plain English
This study focused on a rare type of cancer called uterine leiomyosarcoma, which is aggressive and has few treatment options. Researchers found that diagnosing it is tricky because its symptoms can look like those of other non-cancerous conditions, and while imaging techniques like MRI and CT scans are used to help distinguish it, there isn't a single reliable test. Effective treatment often involves surgery for early-stage cases, and further therapies may be needed for more advanced forms of the disease, making the involvement of multiple specialists important for the best care. Who this helps: This research benefits patients with uterine leiomyosarcoma by improving diagnosis and treatment planning.

Plain English
This study focused on a very rare type of cancer called primary ovarian leiomyosarcoma, which makes up less than 0.1% of ovarian cancers. The researchers looked at 7 cases diagnosed over ten years and found that 71% of the tumors had changes in a gene called TP53, and 57% had changes in another gene called PTEN. Understanding these genetic changes is important because it can lead to better treatment options for this rare cancer. Who this helps: This helps patients with primary ovarian leiomyosarcoma and their doctors.

Plain English
This study looked at how often urinary tract injuries happen during gynecological surgeries and how to manage them. It found that bladder injuries occur in about 0.24% of non-cancer surgeries and between 0.4-3.7% of cancer surgeries, while ureteral injuries happen in about 0.08% of non-cancer and 0.39-1.1% of cancer surgeries. Understanding and quickly identifying these injuries is important because delayed diagnosis can lead to serious problems for patients, including painful complications. Who this helps: This helps patients undergoing gynecological surgery by improving their care and reducing risks.

Plain English
This study looked at how brain tumors from ovarian cancer appear on scans and how different factors affect survival in patients who had surgery. Researchers analyzed data from 106 patients and found that most had a specific type of ovarian cancer and that 79% of the brain tumors showed areas of dead tissue. Notably, patients with a BRCA mutation lived longer—averaging 46 months after surgery compared to 37 months for those without it—and the study highlights the importance of finding these tumors early for better treatment outcomes. Who this helps: This research benefits ovarian cancer patients by improving understanding of their brain metastases and treatment options.

Plain English
This study looked at how well a new imaging method called full-field optical coherence tomography (FF-OCT) can identify cancer in lymph nodes during surgery for gynecological cancers. Researchers tested this method on 80 lymph nodes and found it to be very accurate, with a 97.6% overall accuracy rate, 92.3% sensitivity for detecting cancer, and 98.2% specificity for correctly identifying healthy nodes. This is important because it could help doctors make better decisions during surgery, ensuring patients get the right treatment without unnecessary procedures. Who this helps: This helps patients undergoing gynecological cancer surgeries.

Plain English
This study looked at different markers found in high-grade serous ovarian cancer (HGSOC) to find better ways to diagnose and treat the disease. Researchers found that EDA fibronectin was the most common marker and was present at higher levels in metastatic tumors compared to the original tumors, suggesting it could be a strong target for new treatments. The study analyzed tissue samples from 102 patients and highlighted the need for more research on therapies targeting EDA-FN. Who this helps: This helps patients with high-grade serous ovarian cancer by opening doors to potential new treatments.

Plain English
This study looked at genetic changes in advanced non-small-cell lung cancer patients, specifically focusing on neuregulin 1 (NRG1) variants that have unclear significance. Researchers found that 8% of the patients had these NRG1 variants, and those with NRG1 mutations had shorter times without disease worsening (12 months) compared to those without the mutations (26 months), and also lived shorter overall (20 months vs. 34 months). This is important because it highlights that NRG1 variants may indicate a worse outlook for patients, suggesting a need for better management strategies for these individuals. Who this helps: This helps doctors and patients with advanced non-small-cell lung cancer, particularly those with EGFR mutations.

Plain English
This study examined the mental stress, experiences of violence, and food insecurity facing women visiting a gynecological clinic in Italy. Among 408 women surveyed, 37.2% reported psychological distress, 33.3% experienced violence, and 14.7% faced food insecurity. These findings highlight significant social issues affecting women's health, emphasizing the need for better support systems to help those struggling with economic difficulties and violence. Who this helps: This helps women facing gynecological health issues, particularly those dealing with violence and economic hardship.

Plain English
The study looked at the outcomes of a minimally invasive surgery for women with early-stage endometrial cancer, focusing on procedures like hysterectomy and node mapping to check for cancer spread. Out of 210 patients, nearly all successfully had their sentinel nodes mapped, with 19 showing cancer presence in the para-aortic area, and only a small percentage experienced serious complications. This is important because it indicates that these surgical methods are safe and effective for staging the disease, and the findings pave the way for better treatment planning. Who this helps: This helps women diagnosed with early-stage endometrial cancer.

Plain English
This study focused on a type of endometrial cancer called No Specific Molecular Profile (NSMP), which makes up about 30-40% of all cases. Researchers found that 92% of the 253 patients studied had at least one genomic change that could be targeted with specific treatments, highlighting key alterations in genes like PTEN (found in 88% of patients) and PIK3CA (found in 42% of patients). These findings are important because they point to the potential for personalized therapies that could improve treatment outcomes based on individual genetic profiles. Who this helps: This benefits patients with NSMP endometrial cancer and their doctors.

Plain English
This study looked at a new hemostatic powder called AMP-SPH, comparing it to standard care during gynecological surgeries. Among the 90 patients, 97.7% achieved hemostasis (stopping bleeding) with the new powder, slightly better than the 93.5% with standard care. Notably, only 4.8% of those using the powder needed blood products compared to 17.9% in the standard care group. Who this helps: This helps patients undergoing gynecological procedures by potentially reducing bleeding and the need for blood transfusions.

Plain English
This study looked at the outcomes of patients who underwent a major surgical procedure called pelvic exenteration to treat certain gynecologic cancers between 2005 and 2023. Out of 862 patients, 78.4% had no cancer at the surgical margins after surgery. The research found that patients with certain factors, like positive surgical margins or lymph node involvement, had lower chances of living without cancer after five years, with survival rates ranging from 43.7% to just 8% based on risk levels. Who this helps: This helps doctors make better treatment decisions and guide patients on what to expect after surgery.

Plain English
This study examined the effects of a combination treatment of chemotherapy and an immune therapy called oregovomab on patients with advanced ovarian cancer. It found that patients receiving the combination treatment (carboplatin, paclitaxel, and oregovomab) had a median overall survival of 121.3 months, compared to 64.7 months for those receiving only chemotherapy, indicating that the immune therapy significantly improved survival rates. This matters because it shows a promising way to enhance the effectiveness of existing cancer treatments for patients with advanced ovarian cancer. Who this helps: Patients with advanced ovarian cancer.

Plain English
This paper reviewed how lifestyle and diet can help manage polymycystic ovary syndrome (PCOS), which is a complex condition affecting hormone and metabolism. The study found that regular physical activity is essential for improving hormones and metabolism, and it can help women with PCOS maintain or lose weight. While there isn’t a single diet everyone agrees on, eating low-glycemic foods with plenty of fiber is recommended for those with high insulin levels. Who this helps: This benefits women with PCOS and their healthcare providers.

Plain English
This study compared two surgical methods for treating pelvic organ prolapse: laparoscopic sacral colpopexy (LSCP) and laparoscopic lateral suspension (LLS). Both methods showed similar success rates in correcting prolapse, with LLS being faster, taking about 43.1 minutes less time on average. This matters because using LLS could reduce surgery time without compromising effectiveness, although more research is needed to confirm its long-term benefits. Who this helps: This helps patients undergoing surgery for pelvic organ prolapse.

Plain English
This study looked at different international guidelines for treating patients with vulvar cancer from organizations like NCCN, ASCO, and FIGO. The researchers found that while many guidelines agree on key treatment steps, there were some differences in specific recommendations, which could lead to varying care for patients. Understanding these differences is important because it can help improve treatment consistency and outcomes for those diagnosed with vulvar cancer. Who this helps: This benefits patients with vulvar cancer and their healthcare providers.

Plain English
This study looked at how safe and effective the cancer drug niraparib is for older women (75 years and older) with advanced tubo-ovarian cancer. Researchers found that most patients could tolerate the drug well, with common issues being dose reductions rather than severe side effects. In fact, the average time patients stayed without their cancer worsening was about 16 months for those over 75, similar to younger groups, showing that age shouldn’t stop older patients from receiving this treatment. Who this helps: This helps older cancer patients who may benefit from niraparib treatment.

Plain English
This study looked at how adding tests for specific serum proteins to existing clinical and ultrasound information can improve the ability to predict whether ovarian tumors are cancerous. Researchers analyzed data from 932 patients and found that using serum proteins, especially HE4 and CA125, increased the accuracy of predicting malignant tumors, raising the predictive power score from 0.91 to 0.94. This is important because better predictions can lead to earlier and more accurate treatments for patients with ovarian tumors. Who this helps: Patients with ovarian tumors and their doctors.

Plain English
This study looked at how to predict whether women with ovarian cancer would respond well to chemotherapy before surgery. Researchers found that a specific measure called KELIM, which indicates how well the tumors respond to treatment, was a strong predictor of better outcomes after surgery, with odds of 3 to 4 times higher for achieving successful surgery and complete tumor response when patients had a favorable KELIM score. This is important because it helps doctors make better treatment decisions for their patients and may lead to more effective therapies in the future. Who this helps: This helps patients with ovarian cancer by improving treatment planning.

Plain English
This study looked at the oral health of cancer patients, specifically those with bone metastatic cancer and head and neck cancer, compared to healthy patients. It found that patients with head and neck cancer had significantly worse oral health, being 2.36 times more likely to have poor oral health than healthy individuals, while bone metastatic cancer patients showed no significant differences from the controls. The research also identified age over 70 and smoking as major risk factors for poor oral health. Who this helps: This helps patients with head and neck cancer and health professionals involved in their care.

Plain English
This study looked at using robotic surgery to treat a woman in her 50s who had a recurrence of ovarian cancer after receiving a kidney transplant. The surgery, which involved removing a cancerous lesion near her rectum, was successful with no complications, and the patient remained cancer-free two years later. This matters because it shows that minimally invasive robotic surgery can be a safe and effective option for frail patients with a history of organ transplants who have recurring ovarian cancer. Who this helps: This helps kidney transplant recipients facing ovarian cancer recurrence.

Plain English
This study focused on using the Da Vinci Single-Port robotic surgery system to treat a 66-year-old obese woman with endometrial cancer, who had a body mass index (BMI) of 44. The surgery took a total of 128 minutes, resulted in an estimated blood loss of 200 mL, and the patient spent just 2 days in the hospital without any postoperative complications. These findings are significant because they show that robotic surgery can be successfully performed in obese patients, offering benefits like quicker recovery and less pain, which may lead to better treatment options for this group. Who this helps: This benefits obese patients with endometrial cancer.

Plain English
This study looked at a new surgical method called "The Ship Theory" to perform laparoscopic hysterectomies on women with enlarged uteri, which can be difficult and risky for surgeons. Using this approach, a surgeon was able to successfully remove a large uterus (measuring 189 x 158 x 148 mm) in a 51-year-old woman, with a surgery time of about 90 minutes and minimal blood loss of less than 50 mL. This method is important because it makes the surgery safer and more effective, reducing risks during the procedure. Who this helps: This helps patients who need a hysterectomy for enlarged uteri.

Plain English
Researchers studied how reducing the dose of the cancer drug olaparib affects patients with recurring ovarian cancer caused by BRCA mutations. They looked at 87 patients from 2019 to 2022 and found that those who had their dose lowered (to 500 mg or 400 mg) had similar or better survival rates compared to those who stayed on the full dose of 600 mg. Specifically, the median progression-free survival was 27 months for the full dose, compared to 28 months for the middle dose and 32 months for the lower dose, showing that reducing the dose does not harm treatment effectiveness, even though 52% of patients required a dose reduction due to side effects. Who this helps: This benefits patients with recurrent ovarian cancer who may experience side effects from traditional dosing.

Plain English
This study looked at how young women (ages 15-39) felt after receiving treatment aimed at preserving their ability to have children while being treated for atypical endometrial hyperplasia or endometrioid endometrial cancer. Researchers contacted 32 patients who had undergone this treatment and found that 93.9% had no signs of disease after a median follow-up of about 29 months, with a pregnancy rate of 60% among those trying to conceive. Even though most had positive treatment outcomes and low regret about their decisions, many still had significant concerns about their fertility, potential infertility, and their future children's health. Who this helps: This benefits young women facing these cancer diagnoses, as well as their families and healthcare providers.

Plain English
This study looked at the treatment of patients with epithelial ovarian cancer who relapsed within six months after their first chemotherapy. Researchers found that giving platinum treatment again led to better survival outcomes compared to other treatments; patients who received platinum had a median progression-free survival of 9 months, while those who received other treatments had only 5 and 6 months. This is important because it offers a potentially effective treatment option for patients whose cancer comes back quickly after initial therapy. Who this helps: Patients with epithelial ovarian cancer who relapse quickly after first treatment.

Plain English
This study looked at a new way to combine personal storytelling and questionnaires about health to better understand the quality of life for patients with advanced breast cancer. It involved 29 patients and 6 oncologists in Italy, who found that using a digital diary for patients' stories helped improve communication and personalize care. Specifically, 10 patients felt their quality of life improved through this approach, showing that sharing personal experiences can provide valuable insights that standard questionnaires might miss. Who this helps: This approach benefits patients with metastatic breast cancer and their doctors by fostering better communication and more tailored care.

Plain English
This study investigated two methods of providing oxygen to patients under general anesthesia: high-flow nasal oxygen and mechanical ventilation using a laryngeal mask. The researchers found that both methods worked equally well, with 99% success rates for both, but patients using high-flow nasal oxygen experienced fewer respiratory issues after surgery (2% compared to 19% for the laryngeal mask). This is important because it suggests that high-flow nasal oxygen can be a safe and effective option for supporting breathing during surgery. Who this helps: This benefits patients undergoing surgeries requiring general anesthesia.

Plain English
Researchers created standardized assessment forms for training medical professionals in major childbirth emergencies, like shoulder dystocia and postpartum hemorrhage. They gathered feedback from expert panels over several rounds, achieving strong consensus ratings—many emergencies received scores above 75%, with postpartum hemorrhage having the highest at 96%. This is important because it ensures that training for dealing with these critical situations is consistent and effective, ultimately leading to better outcomes for mothers and babies. Who this helps: This benefits doctors and healthcare providers who manage childbirth emergencies.